ArticleJACC. Case reports2026
Recurrent Myocarditis After COVID Vaccination in a Patient With FLNC Mutation Undergoing Treatment for Lymphoma.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFilamin C (FLNC) variants are often associated with structural cardiomyopathies but rarely myocarditis. CASE SUMMARY: A 60-year-old man with newly diagnosed B-cell lymphoma and initiation of cancer therapy presented with substernal chest pain. He had experienced myocarditis 2 years ago from a COVID-19 vaccine or possible infection; however, he received another COVID-19 booster in anticipation of upcoming cancer therapy. He was diagnosed with acute myocarditis, and his course was complicated by cardiac arrest requiring multidisciplinary management. Outpatient genetic testing revealed a pathogenic FLNC variant. DISCUSSION: This report highlights the case of a patient with FLNC mutation who developed recurrent myocarditis in the setting of exogenous factors, including the COVID-19 vaccine and a history of lymphoma and immunotherapy. TAKE-HOME MESSAGES: Myocarditis may be the initial presentation for certain genetic cardiomyopathies. Genetic testing should be strongly considered in patients with multiple episodes of myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.